Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kristi L Berger

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Viruses|October 14, 2011
Possibilities for RNA interference in developing hepatitis C virus therapeuticsKristi L Berger, Glenn Randall
Communicative & Integrative Biology|March 3, 2010
Potential roles for cellular cofactors in hepatitis C virus replication complex formationKristi L Berger, Glenn Randall
Journal of Virology|June 24, 2011
Hepatitis C virus stimulates the phosphatidylinositol 4-kinase III alpha-dependent phosphatidylinositol 4-phosphate production that is essential for its replicationKristi L Berger, Sean M Kelly, Tristan X Jordan, et al.
Virology|December 30, 2014
Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositidesVineela Chukkapalli, Kristi L Berger, Sean M Kelly, et al.
Plos Pathogens|December 31, 2009
RNA interference and single particle tracking analysis of hepatitis C virus endocytosisKelly E Coller, Kristi L Berger, Nicholas S Heaton, et al.
Plos Pathogens|January 14, 2012
Molecular determinants and dynamics of hepatitis C virus secretionKelly E Coller, Nicholas S Heaton, Kristi L Berger, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 22, 2010
Dengue virus nonstructural protein 3 redistributes fatty acid synthase to sites of viral replication and increases cellular fatty acid synthesisNicholas S Heaton, Rushika Perera, Kristi L Berger, et al.
Antimicrobial Agents and Chemotherapy|July 24, 2013
Viral resistance in hepatitis C virus genotype 1-infected patients receiving the NS3 protease inhibitor Faldaprevir (BI 201335) in a phase 1b multiple-rising-dose studyKristi L Berger, Lisette Lagacé, Ibtissem Triki, et al.
Virology|October 3, 2002
Telomerase activation in cervical keratinocytes containing stably replicating human papillomavirus type 16 episomesDaniel L Sprague, Stacia L Phillips, Calista J Mitchell, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 7, 2016
Safety and efficacy of faldaprevir in combination with pegylated interferon α-2b and ribavirin in Japanese patients with genotype-1 chronic hepatitis C virus infectionShuhei Nishiguchi, Yasuhisa Urano, Keiko Suzaki, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Viruses|October 14, 2011
Possibilities for RNA interference in developing hepatitis C virus therapeuticsKristi L Berger, Glenn Randall
Communicative & Integrative Biology|March 3, 2010
Potential roles for cellular cofactors in hepatitis C virus replication complex formationKristi L Berger, Glenn Randall
Journal of Virology|June 24, 2011
Hepatitis C virus stimulates the phosphatidylinositol 4-kinase III alpha-dependent phosphatidylinositol 4-phosphate production that is essential for its replicationKristi L Berger, Sean M Kelly, Tristan X Jordan, et al.
Virology|December 30, 2014
Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositidesVineela Chukkapalli, Kristi L Berger, Sean M Kelly, et al.
Plos Pathogens|December 31, 2009
RNA interference and single particle tracking analysis of hepatitis C virus endocytosisKelly E Coller, Kristi L Berger, Nicholas S Heaton, et al.
Plos Pathogens|January 14, 2012
Molecular determinants and dynamics of hepatitis C virus secretionKelly E Coller, Nicholas S Heaton, Kristi L Berger, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 22, 2010
Dengue virus nonstructural protein 3 redistributes fatty acid synthase to sites of viral replication and increases cellular fatty acid synthesisNicholas S Heaton, Rushika Perera, Kristi L Berger, et al.
Antimicrobial Agents and Chemotherapy|July 24, 2013
Viral resistance in hepatitis C virus genotype 1-infected patients receiving the NS3 protease inhibitor Faldaprevir (BI 201335) in a phase 1b multiple-rising-dose studyKristi L Berger, Lisette Lagacé, Ibtissem Triki, et al.
Virology|October 3, 2002
Telomerase activation in cervical keratinocytes containing stably replicating human papillomavirus type 16 episomesDaniel L Sprague, Stacia L Phillips, Calista J Mitchell, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 7, 2016
Safety and efficacy of faldaprevir in combination with pegylated interferon α-2b and ribavirin in Japanese patients with genotype-1 chronic hepatitis C virus infectionShuhei Nishiguchi, Yasuhisa Urano, Keiko Suzaki, et al.
Pageof 2